Oncology News | pharmaphorum

News

AbbVie bags EU nod for key drug from ImmunoGen takeover

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant

News

Syndax gets FDA okay for first-in-class leukaemia drug

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.

News

MSD joins PD-1/VEGF push in cancer with LaNova deal

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.

News

Bone marrow aspirate showing the histologic correlate of multiple myeloma under the microscope, H&E stain

GSK hails survival data with revived myeloma drug Blenrep

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat

News

Metsera gets $215m for obesity trials, and other financings

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

AbbVie bags EU nod for key drug from ImmunoGen takeover

Syndax gets FDA okay for first-in-class leukaemia drug

MSD joins PD-1/VEGF push in cancer with LaNova deal

GSK hails survival data with revived myeloma drug Blenrep

Metsera gets $215m for obesity trials, and other financings

BioNTech buys Biotheus and its Keytruda rival for $950m

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks